Merck snags priority review for Prevnar 13 rival — just one month after Pfizer sent its follow-on to the FDA
Almost a decade after Prevnar 13 was approved — going on to become Pfizer’s best-selling product — Merck is one step away from having a rival vaccine …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
